PCN83 Healthcare Resource Utilization (HCRU) of Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer (EC/GEJC) Receiving Adjuvant Nivolumab Treatment Versus Placebo:
Abstract
Authors
R. Lawrance P. Singh A. Leso A. Moreno-Koehler B. Padilla X. Sun F. Taylor S. Blum